hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06365619, orgStudyIdInfo id: HCI168525, briefTitle: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma, acronym: NeoRelapse, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2029-08, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Utah, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to study the impact of Neoadjuvant ipilimumab and nivolumab for melanoma patients that had recurrence during or after adjuvant anti-PD-1 therapy.Participants will receive 2 cycles of treatment prior to their standard of care surgery. After surgery participants will receive standard of care adjuvant therapy and be followed for response., conditionsModule conditions: Melanoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Ipilimumab, interventions name: Nivolumab, outcomesModule primaryOutcomes measure: Rate of pathologic response rate (pCR, mCR/nCR, or pPR) at the time of surgery., secondaryOutcomes measure: Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment., secondaryOutcomes measure: Rate of adverse events that occur within 30 days post-surgery., secondaryOutcomes measure: Rate of Event Free Survival (EFS)., secondaryOutcomes measure: Rate of Overall Survival (OS)., secondaryOutcomes measure: Objective response rate (ORR) defined as the proportion of subjects achieving a confirmed PR and CR as defined by RECIST 1.1 prior to surgical resection., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Huntsman Cancer Institute, city: Salt Lake City, state: Utah, zip: 84112, country: United States, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06365606, orgStudyIdInfo id: CLS-015A, briefTitle: Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis Syphilis Ab Test at the Point- Of-Care Sites, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2024-04-10, completionDateStruct date: 2024-05-29, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, descriptionModule briefSummary: This study is a prospective cross-sectional study in which surgically non-invasive sample- taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and plasma (i.e., obtained through venous EDTA whole blood collection and processing) are collected by a healthcare professional. The collected samples are tested in a routine testing environment, i.e., healthcare providers at, conditionsModule conditions: Syphilis Infection, conditions: Syphilis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: DOUBLE, maskingDescription: Participants and the healthcare providers are not aware of the syphilis status., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 4500, type: ESTIMATED, armsInterventionsModule interventions name: iStatis Syphilis Ab Test, outcomesModule primaryOutcomes measure: Sensitivity and specificity of the iStatis Syphilis Ab Test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Epicentre Health Research, status: RECRUITING, city: Hillcrest, state: KwaZulu Natal, zip: 3650, country: South Africa, contacts name: Cherie Cawood, role: CONTACT, phone: +27 828202955, email: cheriec@epicentre.org.za, hasResults: False
protocolSection identificationModule nctId: NCT06365580, orgStudyIdInfo id: Kylo-0603-I-C01, briefTitle: Dose Escalation Study of Kylo-0603 in Healthy Subjects, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-23, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Kylonova (Xiamen) Biopharma co., LTD., class: INDUSTRY, descriptionModule briefSummary: This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of food of Kylo-0603 in healthy Chinese adult subjects., conditionsModule conditions: Nonalcoholic Steatohepatitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 124, type: ESTIMATED, armsInterventionsModule interventions name: Kylo-0603 capsule, interventions name: Placebo, outcomesModule primaryOutcomes measure: incidence of adverse events, secondaryOutcomes measure: Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax), secondaryOutcomes measure: PK parameter of time of maximum observed concentration (Tmax), secondaryOutcomes measure: PK parameter of area under the concentration time curve (AUC), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: The first affiliated hospital, Zhejiang University School of Medicine, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06365554, orgStudyIdInfo id: 2, briefTitle: On-Premise and Remote Robotic Neurointervention, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Remedy Robotics, Inc., class: INDUSTRY, collaborators name: Unity Health Toronto, descriptionModule briefSummary: This study is a prospective, single arm, single-center study to evaluate the safety and feasibility of the Remedy Robot for on premise and remote robotic Neurointervention., conditionsModule conditions: Cerebrovascular Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Remedy Robot, outcomesModule primaryOutcomes measure: Procedural safety, primaryOutcomes measure: Procedural Technical Success, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06365541, orgStudyIdInfo id: GYLLPJ-2024006, briefTitle: The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-08-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: The People's Hospital of Gaozhou, class: OTHER, descriptionModule briefSummary: Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance., conditionsModule conditions: The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Exploring the efficacy and safety of dapagliflozin in improving heart failure in dialysis patients by the analysis and comparison of patients' own data before and after dapagliflozin treatment, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Dapagliflozin, outcomesModule primaryOutcomes measure: N-terminal B-type natriuretic peptide precursor (NT-proBNP), primaryOutcomes measure: Left ventricular ejection fraction (LVEF), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The People's Hospital of Gaozhou, status: RECRUITING, city: Maoming, state: Guangdong, zip: 525200, country: China, contacts name: Mingsheng Zhu, role: CONTACT, phone: 15016656405, email: ms160@163.com, geoPoint lat: 21.65, lon: 110.9, hasResults: False
protocolSection identificationModule nctId: NCT06365528, orgStudyIdInfo id: 2023-0232, briefTitle: Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-07-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Hospital de Clinicas de Porto Alegre, class: OTHER, collaborators name: Hospital Moinhos de Vento, collaborators name: Irmandade Santa Casa de Misericórdia de Porto Alegre, descriptionModule briefSummary: The aim of this multicenter randomized clinical trial is to compare the tunneling technique of PICC insertion with the non-tunneled insertion technique in the incidence of the combined or isolated outcome of catheter-related bloodstream primary infection, thrombosis, obstruction, and accidental dislodgement in the adult population within a period of up to 30 days., conditionsModule conditions: CLABSI - Central Line Associated Bloodstream Infection, conditions: Deep Vein Thrombosis, conditions: Dislodged Catheter, conditions: Occlusion, conditions: Catheter Rupture, conditions: Catheter (Other); Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: Prospective Randomized Open, Blinded End-point (PROBE Study), whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 840, type: ESTIMATED, armsInterventionsModule interventions name: Subcutaneous tunnelling, interventions name: Non-tunnelling, outcomesModule primaryOutcomes measure: End of therapy or catheter removal free from complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital de Clínicas de Porto Alegre, city: Porto Alegre, country: Brazil, contacts name: Eneida R Rabelo da Silva, ScD, role: CONTACT, geoPoint lat: -30.03306, lon: -51.23, hasResults: False
protocolSection identificationModule nctId: NCT06365489, orgStudyIdInfo id: 113293, briefTitle: Comparison of Brachial Wrist Index Before and After Implantation of Arteriovenous Fistulas, Based on Brachial Artery, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-12-11, primaryCompletionDateStruct date: 2023-02-20, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Golestan University of Medical sciences, class: OTHER, descriptionModule briefSummary: Arterio-Venous Fistula (AVF) is the most recommended vascular access for hemodialysis. Steal syndrome is a potential complication of AVF implantation and occurs secondary to diversion of the arterial flow of a limb to the venous system resulting in limb ischemia. Measuring wrist pressure compared to arm pressure before and after fistula implantation can be a suitable tool in predicting the possibility of Steal syndrome. In this study, the ratio of wrist to arm pressure and its relationship with Steal syndrome symptoms before and after fistula implantation are investigated., conditionsModule conditions: Vascular Access Complication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 78, type: ACTUAL, outcomesModule primaryOutcomes measure: Early post operative WBI changes following AVF implantation, primaryOutcomes measure: Two-week post operative WBI changes following AVF implantation, primaryOutcomes measure: Three-month post operative WBI changes following AVF implantation, secondaryOutcomes measure: Correlation between WBI changes following AVF implantation with age, secondaryOutcomes measure: Correlation between WBI changes following AVF implantation with sex, secondaryOutcomes measure: Correlation between WBI changes following AVF implantation with co-morbidities, secondaryOutcomes measure: Correlation between WBI changes following AVF implantation with steal syndrome, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pezhman Kharazm, MD, city: Gorgan, state: Golestan, zip: 4917956808, country: Iran, Islamic Republic of, geoPoint lat: 36.8427, lon: 54.44391, hasResults: False
protocolSection identificationModule nctId: NCT06365476, orgStudyIdInfo id: 202309126RIND, briefTitle: FlexWave Trial: Efficacy of Extracorporeal Shock Wave Therapy in Post-Stroke Upper Limb Spasticity, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-04-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity., conditionsModule conditions: Stroke, conditions: Spasticity, Muscle, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: focused extracorporeal shock wave therapy (ESWT), outcomesModule primaryOutcomes measure: passive range of motion for the wrist and finger joints, primaryOutcomes measure: hand grip strength, primaryOutcomes measure: Visual Analogue Scale (VAS), primaryOutcomes measure: modified Ashworth scale (MAS), primaryOutcomes measure: modified Tardieu scale (MTS), secondaryOutcomes measure: Fugl-Meyer Assessment for the Upper Extremity (FMA-UE), secondaryOutcomes measure: Action Research Arm Test (ARAT), secondaryOutcomes measure: Barthel index, secondaryOutcomes measure: Functional Independence Measure (FIM), secondaryOutcomes measure: ultrasound assessment, secondaryOutcomes measure: Box and Block Test, secondaryOutcomes measure: Wolf Motor Function Test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Physical Medicine & Rehabilitation, National Taiwan University Hospital, status: RECRUITING, city: Taipei, zip: 100, country: Taiwan, contacts name: Shu-mei Yang, MD, role: CONTACT, phone: 886-2- 23123456, email: b99401109@gmail.com, contacts name: Shu-mei Yang, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06365463, orgStudyIdInfo id: URIS202401, briefTitle: Telerehabilitation to Improve Balance and Mobility in Patients After Stroke, acronym: TeleHome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: University Rehabilitation Institute, Republic of Slovenia, class: OTHER, descriptionModule briefSummary: Telerehabilitation is an effective rehabilitation method that allows patients to receive physiotherapy remotely in their homes. The purpose of this study was to investigate the effects of home-based remote group training for balance and mobility on activities and body functions., conditionsModule conditions: Hemorrhagic Stroke, conditions: Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Telerehabilitation, outcomesModule primaryOutcomes measure: Change in balance, primaryOutcomes measure: Change in limits of stability, primaryOutcomes measure: Change in weight-bearing symmetry, secondaryOutcomes measure: Change in mobility, secondaryOutcomes measure: Change in walking speed, otherOutcomes measure: Satisfaction with the remote training, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Rehabilitation Institute, Republic of Slovenia, status: RECRUITING, city: Ljubljana, zip: 1000, country: Slovenia, contacts name: Urška Puh, PT, PhD, role: CONTACT, phone: +386 1 4758152, email: urska.puh@ir-rs.si, geoPoint lat: 46.05108, lon: 14.50513, hasResults: False
protocolSection identificationModule nctId: NCT06365450, orgStudyIdInfo id: IRB00315481, briefTitle: Breast and Cervical Cancer Education Program, acronym: OCEAP, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-22, primaryCompletionDateStruct date: 2024-02-28, completionDateStruct date: 2024-04-05, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Johns Hopkins University, class: OTHER, collaborators name: Older Women Embracing Life, collaborators name: The John G. Bartlett Specialty Practice, descriptionModule briefSummary: The primary goal of this study is to improve cancer literacy in Black women living with HIV and ultimately improve breast and cervical cancer screening uptake. This study involves an educational intervention delivered virtually and in person, depending on the participants' preference., conditionsModule conditions: Cervical Cancer, conditions: Breast Cancer, conditions: Health Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Each participant is required to attend (in person or virtually via Zoom) two educational sessions one on breast cancer and the other on cervical cancer., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Educational Intervention, outcomesModule primaryOutcomes measure: Health Literacy in Cancer Screening as assessed by the Assessment of Health Literacy in Cancer Screening (AHL-C) tool., secondaryOutcomes measure: Number of participants recruited from each community partner, secondaryOutcomes measure: Number of participants who preferred virtual or in person sessions, secondaryOutcomes measure: Number of participants who were lost of follow up, secondaryOutcomes measure: Number of participants who needed help redeeming their gift codes, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Johns Hopkins University School of Nursing, city: Baltimore, state: Maryland, zip: 21205, country: United States, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06365424, orgStudyIdInfo id: KY20151230-5-1, briefTitle: Fenofibrate in Patients With Primary Biliary Cholangitis (PBC), statusModule overallStatus: RECRUITING, startDateStruct date: 2017-04-08, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Xijing Hospital of Digestive Diseases, class: OTHER, descriptionModule briefSummary: An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC), conditionsModule conditions: Primary Biliary Cholangitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 117, type: ESTIMATED, armsInterventionsModule interventions name: Fenofibrate, interventions name: UDCA, outcomesModule primaryOutcomes measure: Treatment emergent adverse events (TEAEs), primaryOutcomes measure: Percentage of patients with biochemical response, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xijing Hospital, status: RECRUITING, city: Xi'an, state: Shaanxi, country: China, contacts name: Ying Han, role: CONTACT, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False